A5046566033- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Renal cell carcinoma treatment
- Mathematical Biology Tumor Growth
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Advanced biosensing and bioanalysis techniques
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Advanced Biosensing Techniques and Applications
- Histone Deacetylase Inhibitors Research
- Genetics, Bioinformatics, and Biomedical Research
- Bioinformatics and Genomic Networks
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Insect Resistance and Genetics
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Immune Cell Function and Interaction
Ideaya Biosciences (United States)
2025
Pfizer (United States)
2020-2023
Quest Diagnostics (United States)
2007-2023
Research Institute of Dallas
2022
Grinnell College
2013
Wake Forest University
2009
University of California, Irvine
2001-2007
Zero to Three
2004
The University of Texas Southwestern Medical Center
2001
Howard Hughes Medical Institute
2001
Phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR), a downstream kinase, are both required for proliferation splenic B cells. However, functions PI3K mTOR in response to different stimuli among cell subsets have not been fully elucidated. We used flow cytometry magnetic sorting examine requirement responses BCR LPS stimulation. BCR-mediated phosphorylation Akt Erk is sensitive catalytic inhibitor wortmannin marginal zone (MZ) follicular (FO) activation inhibited by...
Abstract In this study, we investigate the extracellular and intracellular signals that drive cell cycle progression of activated B cells in absence T help. We find brief engagement receptor is sufficient to induce a single division fraction cells, but survival during successive divisions requires sustained stimulation. contrast, have been shown previously commit multiple following TCR engagement. Both early late are blocked by inhibitors phosphoinositide 3-kinase mammalian target rapamycin...
A total of 100 patients with American Burkitt's lymphoma (AMBL) (mean age, 15 years; M:F ratio 3:1; 3% black) have been treated at the National Cancer Institute since 1964. Eighteen these had jaw involvement, 16 presentation and 2 relapse 1.6:1). None 18 was black. Of presenting initially tumors, 14 were first evaluated by their dentist; 8 years age or older (adults) 6 younger than (children). Toothache perioral numbness most frequent findings in adults, whereas toothache, loose teeth,...
GH levels increase to high concentrations immediately before puberty then progressively decline with age. deficiency (GHD) originating in childhood is treated supplementation foster somatic development during adolescence. It not clear if or how early replacement affects memory adulthood, whether it can prevent the cognitive deficits commonly observed adults childhood-onset GHD. Rats homozygous for Dw-4 mutation (dwarf) do exhibit normal at 4 weeks of age when normally rise and are used model...
Bruton's tyrosine kinase (Btk) acts downstream of phosphoinositide 3-kinase (PI3K) in a pathway required for B cell receptor (BCR)-dependent proliferation. We used DNA microarrays to determine what fraction genes this influences and investigate whether PI3K Btk mediate distinct gene regulation events. As complete loss-of-function mutations alter subpopulations may cause compensatory changes expression, we cells with partial loss function either or Btk. Only about 5% the BCR-dependent...
Abstract Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because outcomes vary markedly within cytogenetic subgroups, additional biological markers needed risk stratification. Experimental Design: We assessed utility measuring pretreatment proteasome chymotrypsin-like, caspase-like, trypsin-like activities in plasma to predict...
Abstract Poly (ADP-Ribose) glycohydrolase (PARG) is an emerging oncology drug target with a unique role in the resolution of DNA damage repair and replication fork restart through hydrolysis (ADP-ribose) (PAR) chains. IDE161 potent, orally bioavailable, small molecule that directly binds active site PARG to impede PAR chain exhibits robust anti-tumor activity preclinical models associated stress. Molecular profiling baseline cell states across 257 tumor lines indicated innate immune...
3513 Background: Encorafenib + binimetinib cetuximab (enco/bini/cetux; triplet) and enco cetux (doublet) regimens improved overall survival objective response rate vs standard of care in pts with previously treated BRAF V600E-mutant mCRC the randomized phase 3 BEACON study. To identify molecular correlates clinical outcome, we performed profiling tumors from Methods: Baseline tumor samples were retrospectively analyzed by whole-exome sequencing (WES) whole transcriptome (WTS) using ImmunoID...
Current diagnostic screening strategies based on karyotyping or fluorescent in situ hybridization (FISH) for detection of chromosomal abnormalities chronic lymphocytic leukemia (CLL) are laborious, time-consuming, costly, and have limitations resolution. Multiplex ligation-dependent probe amplification (MLPA) can simultaneously detect copy number changes multiple loci one simple PCR reaction, making it an attractive alternative to FISH. To enhance the clinical robustness further harness MLPA...
The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated elevated lymphocyte levels the sunitinib arm an abundance innate immune subsets A+Ax arm. Treatment led to greater T-cell repertoire modulation less change...
The signaling enzyme phosphoinositide 3-kinase (PI3K) is activated following B cell receptor (BCR) engagement and by many other receptors on lymphocytes. Mice lacking p85α, the predominant PI3K regulatory isoform, exhibit defects in development activation that are grossly similar to those found mice Bruton's tyrosine kinase (Btk) critical molecules. However, a detailed analysis of splenic subsets p85α-deficient has not been reported. Here we show these deficient four major subsets:...
Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype single-nucleotide polymorphism (SNP) rs1617640 in erythropoietin (EPO) promoter has been shown to associated with decreased EPO expression. We examined association MDS.We genotyped rS1617640 SNP 189 patients MDS, 257 acute myeloid leukemia (AML), 106 lymphoblastic leukemia, 97 chronic lymphocytic 353 and 95...
Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these with a more favorable clinical outcome. We developed an assay for detection NPM1 mu
Phosphoinositide 3-kinase (PI3K) is a ubiquitously expressed signaling enzyme that plays an integral role in development and activation of B cells. cell receptor (BCR)-driven proliferation completely blocked either cells lacking the p85alpha regulatory isoform PI3K or wild-type treated with pharmacological inhibitors. However, contribution to early events has not been fully investigated. Here we show have impairments are both quantitatively qualitatively different from those Loss results...
<div>Abstract<p>The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (<i>N</i> = 886) with advanced renal cell carcinoma treated first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated elevated lymphocyte levels the sunitinib arm an abundance innate immune subsets A+Ax arm. Treatment led to...
<div>Abstract<p>The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (<i>N</i> = 886) with advanced renal cell carcinoma treated first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated elevated lymphocyte levels the sunitinib arm an abundance innate immune subsets A+Ax arm. Treatment led to...
<p>Supplementary Figure S1 shows forest plots of PFS according to numbers circulating cell populations in the overall trial population (both arms combined) at baseline. Supplementary S2 with A+Ax or sunitinib cytokine, chemokine, protein concentrations peripheral blood baseline and during treatment (cycle 2 day 1). S3 metrics describing TCR repertoire change from cycle 1 vs sunitinib. S4 updated mutation subgroup definitions group. S5 normalized total T cells pretreatment tumors...
<p>Supplementary Figure S1 shows forest plots of PFS according to numbers circulating cell populations in the overall trial population (both arms combined) at baseline. Supplementary S2 with A+Ax or sunitinib cytokine, chemokine, protein concentrations peripheral blood baseline and during treatment (cycle 2 day 1). S3 metrics describing TCR repertoire change from cycle 1 vs sunitinib. S4 updated mutation subgroup definitions group. S5 normalized total T cells pretreatment tumors...